Predictive Role of sTREM in Endovascular Thrombectomy Outcomes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Ischemic Stroke. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Soluble Soluble Triggering Receptors Expressed on Myeloid Cells (sTREM) Predict Outcomes in Stroke Patients Receiving Endovascular Thrombectomy
Overview
Soluble triggering receptor expressed on myeloid cells (sTREM), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. This study is to investigatethe prognostic roles of sTREM (sTREM1 and sTREM2) in patients with ischemic stroke who underwent endovascular thrombectomy (EVT).
Detailed description
For acute ischemic stroke, the current treatment strategy involves timely recanalization by intravenous thrombolysis and endovascular thrombectomy (EVT). Patients receiving EVT are more likely to achieve successful revascularization and long--term functional independence compared with those receiving standard medical treatment.1 In patients receiving EVT, significant predictors of a favorable functional outcome include minor initial stroke severity, successful recanalization, and shorter onset--to--treatment time. However, unfavorable outcomes can occur even after early successful recanalization in some cases.Triggering receptors expressed on myeloid cells (TREM-1 and TREM-2) are a familyof receptors involved in the immune system expressed on a variety of innate cells of the myeloid lineage, including microglia. sTREM, which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. We enrolled adult patients with stroke who received EVT, with blood sampling immediately before (T1) and after EVT (T2), and at 24 hours after EVT (T3). Non--stroke controls and patients with non--EVT stroke were also enrolled. The plasma concentration of sTREM1 and sTREM2 were analyzed by ELISA. The medical information, image findings and levels of plasma sTREM1 and sTREM2 were analyzed to clarify the association with poor functional outcome (modified Rankin Scale 4-6) at 3 months after stroke.
Primary outcome measures
- Dynamic changes in plasma levels of sTREM-1 and sTREM-2 following Endovascular Therapy [Time frame: From baseline to immediately, 24 hours, 3 days, and 7 days after Endovascular Therapy]
Secondary outcome measures (4)
- favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2 [Time frame: 90 days]
- excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1 [Time frame: 30 days]
- early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS) [Time frame: 24 hours]
- Hemorrhagic transformation [Time frame: 72 hours]
Eligibility criteria
Inclusion criteria
- Patients > 18 years old.
- Patients with acute large vessel occlusion within 24 hours of onset who will receive endovascular treatment.
Exclusion criteria
- Impossibility of getting a blood sample.
- Impossibility of performing the test (Invalid results).
- Refusal to provide the informed consent by the patient/relative.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-control
Study locations
China · 1 center
- Department of Neurology — Xuzhou
Identifiers
NCT: NCT06545591 · XYFY2024-KL335-01